{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"description":"CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, Grade (G) 1: fever (temperature \\>=38 degree Celsius), hypotension and/or hypoxia none; G 2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/ facemask or blow-by; G 3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/ facemask, nonrebreather mask, or Venturi mask; G 4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G 1: Mild, G 2: Moderate, G 3: severe, and G 4: life-threatening consequences; urgent intervention indicated. G 5: death related to AE.","groups":[{"description":"All participants who were enrolled and treated in Part 1 and 2 of the study and evaluated for CRS.","id":"OG000","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all enrolled participants who received at least 1 dose of study intervention. Data for this outcome is presented for all participants in Part 1 and 2 of the study (combined) per study design, as all treatment groups utilized the same elranatamab priming regimen (4 mg on Day 1/20 mg on Day 4, followed by 76mg QW) during Cycle 1.","reportingStatus":"POSTED","timeFrame":"Parts 1 and 2: Cycle 1 (28 days)","title":"Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2","type":"PRIMARY","unitOfMeasure":"Participants"}